This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals
by Kinjel Shah
Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $160.46, moving +0.4% from the previous trading session.
Here's How Much a $1000 Investment in AbbVie Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie (ABBV) Laps the Stock Market: Here's Why
by Zacks Equity Research
AbbVie (ABBV) closed at $154.88 in the latest trading session, marking a +0.17% move from the prior day.
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
by Zacks Equity Research
AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Karuna (KRTX) for $330 per share. This transaction is expected to close in the first half of 2024.
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
by Zacks Equity Research
Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $152.59, representing a +0.59% change from its previous close.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $154.04, marking a -0.54% move from the previous day.
Here's How Much You'd Have If You Invested $1000 in AbbVie a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
by Kinjel Shah
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
The Zacks Analyst Blog Highlights AbbVie, NIKE, BHP Group, CME Group and Block
by Zacks Equity Research
AbbVie, NIKE, BHP Group, CME Group and Block are included in this Analyst Blog.
Top Stock Reports for AbbVie, NIKE & BHP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), NIKE, Inc. (NKE) and BHP Group Ltd. (BHP).
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
by Zacks Equity Research
AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
by Zacks Equity Research
The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
by Zacks Equity Research
Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More
by Kinjel Shah
AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.